



Citations and References

Complex Clinical Decisions Podcast Series

SAMHSA's Recovery to Practice (RTP) Clinical Decision Support CME courses offer timely, recovery-oriented information on prescribing and practices for physicians and other clinicians treating people with serious mental illness. The Complex Clinical Decisions podcast series explores challenging scenarios in psychopharmacology from a strength-based, recovery-oriented perspective, with a focus on shared decision-making, relationship building, and scientific and clinical evidence.

Citations and Resources for More Information

Long-acting Injectable Antipsychotics in Mental Health Recovery

Biagi, E., Capuzzi, E., Colmegna, F., Mascarini, A., Brambilla, G., Ornaghi, A., Santambrogio, J., & Clerici, M. (2017). Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. *Adv Ther*, 34(5): 1036–1048. doi: 10.1007/s12325-017-0507-x

Kim B., Lee, S., Yang, Y.K., Park, J., & Chung, Y. (2012). Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons. *Schizophrenia Research and Treatment*, 560836. doi:10.1155/2012/560836.

Brissos, S., Veguilla, M.R., Taylor, D., & Balanzá-Martinez, V. (2014). The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol*, 4(5), 198–219. doi: 10.1177/2045125314540297

Camacho, A., Ng, B., Galangue, B., & Feifel, D. (2008). Use of Risperidone Long-Acting Injectable in a Rural Border Community Clinic in Southern California. *Psychiatry (Edgmont)*, 5(6), 43–49.

Citrome, L. (2017). Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. *Expert Rev Neurother*, 17(10):1029-1043. doi: 10.1080/14737175.2017.1371014

Correll, C.U., Citrome, L., Haddad, P.M., Lauriello, J., Olfson, M., Calloway, S.M., & Kane, J.M. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. (2016). *Journal of Clinical Psychiatry*, 77(supplement 3), 1-33. doi: 10.4088/JCP.15032su1.

Drugs@FDA: FDA Approved Drug Products: <https://www.accessdata.fda.gov/scripts/cder/daf/>

Getzen, H., Beasley, M., D'Mello, DA. (2013). Barriers to utilizing long-acting injectable antipsychotic medications. *Ann Clin Psychiatry*, 25(4): E1–6.

- Interdepartmental Serious Mental Illness Coordinating Committee. (2017). The Way Forward: Federal Action for a System That Works for All People Living With SMI and SED and Their Families and Caregivers. Retrieved from: https://www.samhsa.gov/sites/default/files/programs_campaigns/ismicc_2017_report_to_congress.pdf
- Lachaine, J., Lapierre, M.-E., Abdalla, N., Rouleau, A., & Stip, E. (2015). Impact of Switching to Long-Acting Injectable Antipsychotics on Health Services Use in the Treatment of Schizophrenia. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie*, 60(3 Suppl 2), S40–S47.
- Llorca PM et al. (2013). Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. *BMC Psychiatry*, 13(1):340.
- Potkin S, Bera R, Zubek D, Lau G. (2013). Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. *BMC Psychiatry*, 13:261.
- SAMHSA. *Considering the role of antipsychotic medications in my recovery plan*. Retrieved from: http://brss-tacs-decision-tool.samhsa.gov/DA_files/Recovery_pg2.html
- SAMHSA-HRSA Center for Integrated Health Solutions Telebehavioral Health Training and Technical Assistance Series. <https://www.integration.samhsa.gov/operations-administration/telebehavioral-health>
- Viswanathan, M., Golin, C.E., Jones, C.D., Ashok, M., Blalock, S.J., Wines, R.C., Coker-Schwimmer, E.J., Rosen, D.L., Sista, P., & Lohr, K.N. (2012). Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. *Ann Intern Med*, 157(11), 785-95. doi: 10.7326/0003-4819-157-11-201212040-00538
- West, J. C., Marcus, S. C., Wilk, J., Countis, L. M., Regier, D. A., & Olfson, M. (2008). Use of Depot Antipsychotic Medications for Medication Nonadherence in Schizophrenia. *Schizophrenia Bulletin*, 34(5), 995–1001.
- Williams, W., McKinney C., Martinez L., & Benson, C. (2016). Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery. *Journal of Medical Economics*, 19(5). doi: 10.3111/13696998.2015.1131989
- Zaybak, A., Güneş, Ü. Y., Tamsel, S., Khorshid, L. and Eşer, İ. (2007), Does obesity prevent the needle from reaching muscle in intramuscular injections? *Journal of Advanced Nursing*, 58: 552-556. doi:10.1111/j.1365-2648.2007.04264.x
- Brown, M. T., & Bussell, J. K. (2011). Medication Adherence: WHO Cares? *Mayo Clinic Proceedings*, 86(4), 304–314. <http://doi.org/10.4065/mcp.2010.0575>
- Ruppar, T., Ho, M.P., Garber, L. (2017). Overcoming Barriers to Medical Adherence for Chronic Diseases. Center for Disease Control. Retrieved from <https://www.cdc.gov/grand-rounds/pp/2017/20170221-medication-adherence.html>